Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Cancer Prev Res (Phila). 2022 Dec 1;15(12):815-825. doi: 10.1158/1940-6207.CAPR-22-0212.
Older age at diagnosis is consistently associated with worse clinical outcomes in prostate cancer. We sought to characterize gene expression profiles of prostate tumor tissue by age at diagnosis. We conducted a discovery analysis in The Cancer Genome Atlas prostate cancer dataset (n = 320; 29% of men >65 years at diagnosis), using linear regressions of age at diagnosis and mRNA expression and adjusting for TMPRSS2:ERG fusion status and race. This analysis identified 13 age-related candidate genes at FDR < 0.1, six of which were also found in an analysis additionally adjusted for Gleason score. We then validated the 13 age-related genes in a transcriptome study nested in the Health Professionals Follow-up Study and Physicians' Health Study (n = 374; 53% of men >65 years). Gene expression differences by age in the 13 candidate genes were directionally consistent, and age at diagnosis was weakly associated with the 13-gene score. However, the age-related genes were not consistently associated with risk of metastases and prostate cancer-specific death. Collectively, these findings argue against tumor genomic differences as a main explanation for age-related differences in prostate cancer prognosis.
Older age at diagnosis is consistently associated with worse clinical outcomes in prostate cancer. This study with independent discovery and validation sets and long-term follow-up suggests that prevention of lethal prostate cancer should focus on implementing appropriate screening, staging, and treatment among older men without expecting fundamentally different tumor biology.
在前列腺癌中,诊断时的年龄越大与临床结局越差相关。我们试图通过诊断时的年龄来描述前列腺肿瘤组织的基因表达谱。我们在癌症基因组图谱前列腺癌数据集(n = 320;29%的男性在诊断时年龄超过 65 岁)中进行了一项发现分析,使用诊断时年龄和 mRNA 表达的线性回归,并调整了 TMPRSS2:ERG 融合状态和种族。该分析确定了 13 个年龄相关的候选基因,假发现率(FDR)<0.1,其中 6 个基因在另外调整了 Gleason 评分的分析中也被发现。然后,我们在健康专业人员随访研究和医师健康研究中的转录组研究(n = 374;53%的男性在诊断时年龄超过 65 岁)中验证了这 13 个与年龄相关的基因。在这 13 个候选基因中,年龄差异的基因表达差异呈方向性一致,且诊断时的年龄与 13 个基因评分弱相关。然而,与年龄相关的基因与转移和前列腺癌特异性死亡的风险并不一致。总的来说,这些发现表明肿瘤基因组差异不是导致前列腺癌预后与年龄相关差异的主要原因。
在前列腺癌中,诊断时的年龄越大与临床结局越差相关。这项具有独立发现和验证集以及长期随访的研究表明,预防致命性前列腺癌应侧重于在没有期望肿瘤生物学有根本不同的情况下,为老年男性实施适当的筛查、分期和治疗。